from The American Heritage® Dictionary of the English Language, 4th Edition
- n. The branch of medicine that deals with tumors, including study of their development, diagnosis, treatment, and prevention.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. The branch of medicine concerned with tumors, including study of their development, diagnosis, treatment, and prevention.
from The Century Dictionary and Cyclopedia
- n. The sum of scientific knowledge concerning tumors.
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. the branch of medicine concerned with the study and treatment of tumors
The word oncology comes from the Greek word meaning
As someone who works in oncology research and sees patients have their insurance deny them treatment or rips it out from under them in the middle of treatment, we must come up with a plan for coverage for anyone who needs it.
The Pediatric Hereditary Cancer Predisposition Program at The Children's Hospital of Philadelphia uses the latest advances in oncology and genetics to provide care and counseling to children with genetic predisposition to cancer.
The one previous study in oncology, looking at multiple myeloma, also found that pharmaceutical studies reported positive results in 74 percent of trials compared to 47 percent of non-industry-sponsored trials. posted by sydney on
Oncopartners, a Latin American oncology development company, and its exclusive partner IBPC, a non-profit oncology research network made up of Brazil's largest public oncology hospitals.
Hammond JM, Orlando LA, Wheeler JL; et al. Reliability of compendia methods for off-label oncology indications.
; et al. Systematic review: reliability of compendia methods for off-label oncology indications.
Â''She didnÂ't really talk about the word Â'cancer, Â 'but the fact that she used the word oncology, it was like, Â'Wow.
Analysts at Bernstein, who upgraded their rating on Roche to "outperform" from "market-perform" in mid-December, believe the Swiss company will be upgraded by investors "if markets became more positive on long-term oncology R&D productivity and less concerned about the prospects of biosimilar versions of Herceptin.
We are not going to get into oncology, which is a big focus of all these big guys.